ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
- PMID: 12384534
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
Abstract
The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy. We have developed a low-molecular-weight EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa(2) ). ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC(50) = 0.033 micro M) that selectively inhibits EGF-stimulated tumor cell growth (IC(50) = 0.054 micro M) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner. The level of expression of EGFR did not determine xenograft tumor sensitivity to ZD1839. Long-term ZD1839 (>3 months) treatment of mice bearing A431 xenografts was well tolerated, and ZD1839 completely inhibited tumor growth and induced regression of established tumors. No drug-resistant tumors appeared during ZD1839 treatment, but some tumors regrew after drug withdrawal. These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen.
Similar articles
-
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.Cancer Res. 2001 Dec 15;61(24):8887-95. Cancer Res. 2001. PMID: 11751413
-
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).Clin Cancer Res. 2002 Nov;8(11):3496-502. Clin Cancer Res. 2002. PMID: 12429640
-
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.Clin Cancer Res. 2000 Dec;6(12):4885-92. Clin Cancer Res. 2000. PMID: 11156248
-
Studies with ZD1839 in preclinical models.Semin Oncol. 2003 Feb;30(1 Suppl 1):12-20. doi: 10.1053/sonc.2003.50028. Semin Oncol. 2003. PMID: 12644980 Review.
-
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?J Cell Physiol. 2003 Jan;194(1):13-9. doi: 10.1002/jcp.10194. J Cell Physiol. 2003. PMID: 12447985 Review.
Cited by
-
Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.Int J Mol Sci. 2024 Oct 18;25(20):11200. doi: 10.3390/ijms252011200. Int J Mol Sci. 2024. PMID: 39456984 Free PMC article.
-
Single-dose clinical pharmacokinetic studies of gefitinib.Clin Pharmacokinet. 2005;44(11):1165-77. doi: 10.2165/00003088-200544110-00004. Clin Pharmacokinet. 2005. PMID: 16231967
-
WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation.Neoplasia. 2005 Apr;7(4):348-55. doi: 10.1593/neo.04544. Neoplasia. 2005. PMID: 15967112 Free PMC article.
-
A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer.PLoS Comput Biol. 2023 Mar 23;19(3):e1010200. doi: 10.1371/journal.pcbi.1010200. eCollection 2023 Mar. PLoS Comput Biol. 2023. PMID: 36952569 Free PMC article.
-
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.Cancer Res. 2007 Jan 15;67(2):827-35. doi: 10.1158/0008-5472.CAN-05-3343. Cancer Res. 2007. PMID: 17234795 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous